PANCREAZE (lipase/protease/amylase)
- Exocrine pancreatic insufficiency
10,500 unit-35,500 unit-61,500 unit capsule,delayed release
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
16,800 unit-56,800 unit-98,400 unit capsule,delayed release
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
2,600 unit-6,200 unit-10,850 unit capsule,delayed release
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
21,000 unit-54,700 unit-83,900 unit capsule,delayed release
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
4,200 unit-14,200 unit-24,600 unit capsule,delayed release
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
Exocrine pancreatic insufficiency
- 2 capsules by oral route 3 times per day with meals and 2 capsules with each snack
- 3 capsules by oral route 3 times per day with meals and 3 capsules with each snack
- 1 capsule by oral route 3 times per day with meals and 1 capsulewith each snack
- 1 capsule by oral route 3 times per day before meals and 1 capsule before each snack
- 2 capsules by oral route 3 times per day before meals and 2 capsules before each snack
- 3 capsules by oral route 3 times per day before meals and 3 capsules before each snack
- 2 capsules by oral route 3 times per day with meals and 1 capsule with each snack
- acarbose
- Glyset
- miglitol
- Precose
Contraindicated
- None
Severe
Moderate
- None
- None
Contraindicated
- Gastrointestinal obstruction
- Meconium ileus
Severe
Moderate
- Crohn's disease
- Fibrosing colonopathy
- Gastrointestinal tract surgery
- Gout
- Hyperuricemia
- Short bowel syndrome
PANCREAZE (lipase/protease/amylase)
- Exocrine pancreatic insufficiency
- None
- None
More Frequent
Severe
Less Severe
- Abdominal pain with cramps
- Abdominal distension
- Cough
- Dizziness
- Flatulence
- Headache disorder
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Biliary calculus
- Diarrhea
- Disorder of the digestive system
- Fibrosing colonopathy
- Gastrointestinal obstruction
- Hyperuricemia
- Nausea
Less Severe
- Pruritus ani
- Pruritus of skin
- Skin rash
- Urticaria
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
None
Amylase
- Severity Level:
C
- Additional Notes: Fda category c in combo products
Lipase
- Severity Level:
C
- Additional Notes: Insufficient data available; consider maternal treatment benefit vs. fetal risk
Protease
- Severity Level:
C
- Additional Notes:
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Amylase
Insufficient data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
Lipase
Insufficient data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insuff data avail;Consider maternal treatment benefit vs possible infant risk |
Protease
Insufficient data available
Insuff data avail;Consider maternal treatment benefit vs possible infant risk
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | Insufficient data available |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
Exocrine pancreatic insufficiency | |
K86.81 | Exocrine pancreatic insufficiency |
0-9 | A-Z |
---|---|
K86.81 | Exocrine pancreatic insufficiency |